Bio-Rad Laboratories, Inc.
NOT FOUND
—
2026-04-22 10:12:13
www.bio-rad.com
NYQ: BIO-B
Explore Bio-Rad Laboratories, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
—
Current Price
NOT FOUND
52W High / Low
$343.12 / $211.43
Stock P/E
—
Book Value
$276.16
Dividend Yield
—
ROCE
2.17%
ROE
10.84%
Face Value
—
EPS
—
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
7,450
Beta
1.16
Debt / Equity
18.58
Current Ratio
5.62
Quick Ratio
4.19
Forward P/E
—
Price / Sales
2.89
Enterprise Value
$7.32 B
EV / EBITDA
16.96
EV / Revenue
2.83
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cerus Corporation | $2.05 | — | $397.8 M | — | -7.17% | -25.66% | $2.96 / $1.15 | $0.33 |
| 2. | 908 Devices Inc. | $7.3 | 13.73 | $267.64 M | — | -16.46% | -25.77% | $9.34 / $4.2 | $3.96 |
| 3. | QuidelOrtho Corporation | $12.89 | — | $877.57 M | — | 1.14% | -46.15% | $38.99 / $11.61 | $28.28 |
| 4. | Perspective Therapeutics, Inc. | $4.55 | — | $478.52 M | — | -47.66% | -41.65% | $6.16 / $1.75 | $2.79 |
| 5. | Rapid Micro Biosystems, Inc. | $2.25 | — | $103.66 M | — | -84.08% | -86.82% | $4.94 / $2.01 | $0.75 |
| 6. | INVO Fertility, Inc. | $2.28 | — | $3.39 M | — | -26.69% | -133.37% | $384 / $1.92 | $-22.34 |
| 7. | Bioventus Inc. | $10.28 | 38.48 | $874.79 M | — | 10.76% | 13.17% | $10.76 / $5.81 | $2.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 693.2 M | 653 M | 651.6 M | 585.4 M | 667.48 M | — |
| Operating Profit | 53.9 M | 63.9 M | 77.1 M | 23.7 M | 58.33 M | — |
| Net Profit | 720 M | -341.9 M | 317.8 M | 64 M | -715.8 M | — |
| EPS in Rs | 142.12 | -67.49 | 62.73 | 12.63 | -141.3 | 23.34 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.58 B | 2.57 B | 2.67 B | 2.8 B |
| Operating Profit | 218.6 M | 269 M | 337.8 M | 475.1 M |
| Net Profit | 759.9 M | -1.84 B | -637.3 M | -3.63 B |
| EPS in Rs | 150 | -364.04 | -125.8 | -716.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.58 B | 9.36 B | 12.3 B | 13.5 B |
| Total Liabilities | 3.12 B | 2.79 B | 3.56 B | 3.89 B |
| Equity | 7.45 B | 6.57 B | 8.74 B | 9.62 B |
| Current Assets | 2.91 B | 3.03 B | 3.05 B | 3.16 B |
| Current Liabilities | 517 M | 467.8 M | 522.8 M | 568.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 532.2 M | 455.2 M | 374.9 M | 194.4 M |
| Investing CF | -189.7 M | -160.2 M | 20.2 M | -1.21 B |
| Financing CF | -283.2 M | -218.8 M | -425.6 M | 973.6 M |
| Free CF | 374.6 M | 266.2 M | 218.2 M | 80.1 M |
| Capex | -157.6 M | -189 M | -156.7 M | -114.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -3.92% | -4.67% | — | — |
| Earnings Growth % | -189.38% | 82.43% | — | — |
| Profit Margin % | -71.86% | -23.86% | -129.45% | — |
| Operating Margin % | 10.48% | 12.65% | 16.95% | — |
| Gross Margin % | 53.73% | 53.42% | 55.93% | — |
| EBITDA Margin % | -83.46% | -24.51% | -161.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.